Evermay Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Evermay Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$55.9K	Hold	107	–	–	0.01%	350
2026 Q2	$53.2K	Buy	107 +75	+234%	+$33.2K	0.01%	350
2026 Q1	$14.3K	Sell	32 -4	-11%	-$1.86K	﹤0.01%	431
2025 Q4	$16.3K	Sell	36 -57	-61%	-$24.6K	﹤0.01%	404
2025 Q3	$36.4K	Hold	93	–	–	﹤0.01%	343
2025 Q2	$41.4K	Hold	93	–	–	0.01%	335
2025 Q1	$45.1K	Hold	93	–	–	0.01%	331
2024 Q4	$37.5K	Hold	93	–	–	0.01%	339
2024 Q3	$43.3K	Sell	93 -213	-70%	-$102K	0.01%	349
2024 Q2	$143K	Hold	306	–	–	0.02%	223
2024 Q1	$128K	Sell	306 -2	-0.6%	-$845	0.02%	249
2023 Q4	$125K	Buy	308 +2	+0.7%	+$739	0.02%	222
2023 Q3	$106K	Hold	306	–	–	0.02%	232
2023 Q2	$108K	Hold	306	–	–	0.02%	232
2023 Q1	$96.4K	Buy	306 +56	+22%	+$16.8K	0.02%	242
2022 Q4	$72.2K	Buy	+250	New	+$76.2K	0.01%	259

Other funds holding VRTX

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $59.1B AUM 41.96% 1-Year Est. Return

Evermay Wealth Management's VRTX Position: Q3 2026 in Review

Evermay Wealth Management held its Vertex Pharmaceuticals (VRTX) position steady in Q3 2026 at 107 shares worth $55.9K. The position accounts for 0.01% of the portfolio, ranked #350.

Evermay Wealth Management first reported a position in VRTX in Q4 2022 and has held it in 16 quarters since. The position peaked at $143K in Q2 2024. 1,212 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Evermay Wealth Management held 107 shares of Vertex Pharmaceuticals worth $55.9K as of Q3 2026.
Evermay Wealth Management left its Vertex Pharmaceuticals share count unchanged in Q3 2026.
Vertex Pharmaceuticals made up 0.01% of Evermay Wealth Management's portfolio in Q3 2026, its #350 holding.
Evermay Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 16 quarters since.
Evermay Wealth Management's Vertex Pharmaceuticals position peaked at $143K in Q2 2024.
1,212 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Evermay Wealth Management's 13F filing for Q3 2026, filed 5 Nov 2026.